Research summary ·
Effects of probiotic or synbiotic supplementation on glycolipid metabolism in patients with coronary heart disease: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 9 Nov 2026.
What was studied
This review pooled randomized trials of probiotics or synbiotics in people with coronary heart disease. It looked at blood sugar and blood fat measures. A trial sequential analysis checked if the data were conclusive. Trials up to 1 May 2026 were searched. The pooled data covered 296 people.
What they found
Fasting blood glucose fell and HDL cholesterol rose. This was based on 192 people. No clear effect was seen on LDL cholesterol, total cholesterol, triglycerides, insulin or blood pressure. Adverse events did not differ clearly. The sequential analysis showed the data for glucose and HDL were not yet conclusive.
What it means for patients
The team says probiotics may be linked to higher HDL cholesterol and lower fasting glucose. They say these changes are not direct proof of heart benefit.
Why it is not certain yet
Certainty was low or very low. No hard heart outcomes were measured. Most studies were done in Iran, and one in China. Strains, doses and lengths varied a lot. Some of the work is not described there. Full data tables are not shown.
Source
Effects of probiotic or synbiotic supplementation on glycolipid metabolism in patients with coronary heart disease: a systematic review and meta-analysis.
PubMed · PMID 42997375We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Coronary artery disease publications